Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

2019 ◽  
Vol 36 (5) ◽  
pp. 433-439 ◽  
Author(s):  
Álvaro Jesús Gómez-Ruiz ◽  
Alida González-Gil ◽  
José Gil ◽  
Álvaro Navarro-Barrios ◽  
Felipe Alconchel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Disease Severity ◽  
Cytoreductive Surgery ◽  
Severity Score ◽  
Recurrent Ovarian Cancer ◽  
Disease Severity Score ◽  
Peritoneal Surface ◽  
Platinum Sensitive ◽  
Ago Score

scholarly journals Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Caixia Jiang ◽  
Zhengyu Li
Keyword(s):  
Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Prediction Models ◽  
Progression Free Survival ◽  
Recurrent Ovarian Cancer ◽  
Operative Morbidity ◽  
Platinum Sensitive ◽  
Secondary Cytoreductive Surgery ◽  
Platinum Based Chemotherapy ◽  
Ago Score

The most advanced epithelial ovarian cancer develops recurrent disease despite maximal surgical cytoreduction and adjuvant platinum-based chemotherapy. Treatment with secondary cytoreductive surgery (SCS) combined with chemotherapy or with chemotherapy alone for patients with platinum-sensitive recurrent ovarian cancer (ROC) is currently under heated discussion. Encouragingly, the results of the AGO DESKTOP III Study and the SOC1/SGOG-OV2 trial, which have been published recently, showed a striking advantage in terms of overall survival (OS) and progression-free survival (PFS) of ROC patients undergoing SCS compared to chemotherapy alone; moreover, a benefit of SCS exclusively for patients with complete gross resection (CGR) was particularly highlighted. CGR is considered the ultimate goal of SCS, on condition that the balance between maximal survival gain and minimal operative morbidity is maintained. Several models have been proposed to predict the rate of CGR, such as the MSK criteria, the AGO score, and the Tian model, over the last 15 years. This summary is mainly about the several previously published prediction models for CGR in SCS of ROC patients and discusses the effectiveness and limitations of these prediction models.

Sign in / Sign up

Export Citation Format

Share Document